Safety and Immunogenicity of Recombinant Zoster Vaccine (LZ901) in Chinese Adults Aged 50-70 Years: A Double-Blind Phase 2 Randomised Clinical Trial

Imagine your body is a bustling city, and its immune system is the tireless police force keeping the streets safe. For decades, this force has been on high alert against a sneaky criminal called the Varicella-Zoster Virus (VZV). You might know this virus better as the cause of chickenpox. Once you've had chickenpox, the virus doesn't leave town; instead, it goes into hiding, sleeping quietly in the nerve cells like a fugitive waiting for the perfect moment to strike. Years later, if your immune police force gets a little tired or distracted—often as we get older—the virus can wake up, causing a painful, blistering rash known as shingles (or herpes zoster). This isn't just a rash; it can leave behind a ghostly, burning pain that lasts for years.

To stop this from happening, scientists have been building "wanted posters" for the virus, called vaccines. These posters show the police force exactly what the criminal looks like so they can recognize and catch it immediately if it tries to wake up. However, not all wanted posters are created equal. Some are so detailed and intense that they make the police force work so hard that the officers themselves get sore, tired, and grumpy (side effects), which makes some people hesitant to get the poster. The big question scientists are asking is: Can we design a new, smarter poster that wakes up the police force just as effectively but without making them feel so beat up? This is the story of a new candidate poster called LZ901, designed specifically for adults aged 50 to 70, to see if it can be both a tough defender and a gentle neighbor.

---

The New Candidate: LZ901

In a recent study, researchers in China decided to test a new vaccine candidate named LZ901. Think of LZ901 not as a simple picture of the virus, but as a high-tech, four-armed robot made from a specific part of the virus (called glycoprotein E) glued to a sturdy handle (an Fc fragment). This design is meant to make the immune system pay extra attention. The scientists wanted to see two things: first, is this robot safe to give to people? And second, does it actually teach the immune system how to fight the virus?

They gathered 450 healthy adults between the ages of 50 and 70. To make sure the results were fair, they played a game of chance to split the group into three teams. One team got a "light" dose of the vaccine (50 micrograms), another team got a "heavy" dose (100 micrograms), and the third team got a placebo—a fake shot that looked just like the real thing but contained no vaccine, just a harmless gel. Everyone got two shots, spaced one month apart, and nobody knew which team they were on until the study was over.

The Safety Check: Did it Hurt?

First, the researchers checked the "ouch" factor. They asked the participants to report any soreness, redness, or swelling where the needle went in, as well as any system-wide feelings like fatigue, fever, or headaches for a week after each shot.

The results were reassuring. In the group that got the light dose, about 39% of people felt some kind of reaction. In the heavy dose group, it was about 39% as well. Interestingly, the group that got the fake shot still had about 28% of people reporting some minor discomfort, which is normal because sometimes our bodies react just to the needle poke or the stress of the visit. Most of the reactions in the vaccine groups were mild (like a sore arm) or moderate (like a headache).

There was one small note of caution: in the heavy dose group, a few people (about 2%) experienced a "grade 3" reaction, which means the symptoms were strong enough to interfere with daily life (like severe fatigue or headache). However, no one in the light dose group had a severe reaction. Crucially, the study found no serious adverse events that were caused by the vaccine. The scary stuff that happened in the study (like hospitalizations) was unrelated to the shots. The researchers also checked for a specific type of antibody that sometimes causes autoimmune trouble, and everyone remained clean.

The Immune Response: Did the Police Wake Up?

Next, the scientists looked at the "wanted posters" the immune system made. They measured two types of antibodies: those that specifically target the virus's surface (anti-gE) and those that recognize the whole virus (anti-VZV).

Before the shots, almost everyone already had some antibodies because they had likely had chickenpox years ago. But after the two doses of LZ901, the immune system went into overdrive.

• The Light Dose (50 µg): The level of anti-gE antibodies jumped up about 17 times higher than before the shot.
• The Heavy Dose (100 µg): This group did even better, with antibodies jumping about 21 times higher.

The antibodies peaked 30 days after the second shot. Even though the levels started to drop slowly over time, they stayed incredibly high. Two years later (at month 24), the light dose group still had antibodies 4.9 times higher than their starting point, and the heavy dose group was still 5.3 times higher. The placebo group, naturally, didn't see any of these jumps.

The study also looked at the "memory" of the immune system against the whole virus (anti-VZV). Here, the heavy dose group again showed slightly higher numbers than the light dose group, though the difference wasn't as huge as with the specific surface antibodies. The key takeaway is that both doses created a strong, long-lasting shield, but the 100 µg dose consistently built a slightly thicker wall.

The Verdict

So, what does this all mean? The study suggests that LZ901 is a safe and effective way to wake up the immune system in adults aged 50 to 70. It's like finding a new training drill for the police force that makes them sharper without giving them a black eye. The "heavy" dose of 100 micrograms seemed to be the champion, creating the strongest immune response while still keeping the side effects manageable.

The researchers didn't claim this vaccine is perfect or that it's ready to be sold in every pharmacy tomorrow. They explicitly stated that this was a Phase 2 trial, meaning it's a middle step to prove the concept works. The next step, which they are already planning, is a massive Phase 3 trial to see if this vaccine actually stops people from getting shingles in the real world. But for now, the data suggests that LZ901, especially at the 100 µg dose, is a very promising candidate to help protect older adults from the painful wake-up call of shingles.